N Engl J Med October 2018 PMID 30146931

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

Download social card

Mentions

246

Peak: 8 in Sep 2020

across 7 sources since Jan 2019

Extended reach

260,218

potential audience

Total likes

846

Video views

37,844

Mentions per month

Jan 2019 – Mar 2024

Where it's discussed

News111 articles
X / Twitter75 posts
Facebook45 posts
Blogs10 articles
YouTube2 videos
Reddit2 posts
Bluesky1 posts

AI synopsis

What people are saying

Numerous discussions highlight the contrasting results of the ASCEND trial, emphasizing that while aspirin reduced serious vascular events, it also led to a 29% increased risk of major bleeding. Phrases like 'the benefits were broadly counterbalanced' and 'no more aspirin for primary prevention' suggest significant concern around the implications of the study’s findings; the urgency of addressing these risks is palpable, evidenced by users questioning longstanding practices with statements such as 'it was embarrassing when the RCT says we weren't quite right.' The tone of these discussions reflects both serious consideration and a shift in perspective.

AgreementModerate agreement

While many discussions acknowledge the findings of the study, there are some differing opinions on the implications for practice.

InterestHigh interest

The posts reflect a strong interest in the topic, as participants discuss both the findings and their broader implications.

EngagementModerate engagement

While there are some deep insights shared, many posts summarize opinions rather than delving deeply into methodology or data analysis.

ImpactHigh impact

The consensus is that the findings could significantly alter clinical practices regarding aspirin use for diabetes patients.

Abstract in brief

Aspirin can lower the risk of serious cardiovascular events (like heart attacks and strokes) in people with diabetes but also increases the risk of major bleeding, especially gastrointestinal bleeding.
In a study with about 15,480 diabetes patients, those taking aspirin had a significantly lower rate of serious vascular events compared to those on placebo (8.5% vs 9.6%).
Despite the benefits in preventing vascular events, the aspirin group experienced more major bleeding incidents (4.1% vs 3.2%), with no significant difference in the incidence of gastrointestinal tract cancer between the two groups.

Read the full abstract

All mentions

Aspirin's Role in Cardiovascular Health and Longevity

Can aspirin really help us live longer? In this video, we explore the role of aspirin in reducing serious cardiovascular events, particularly for individuals with diabetes. Although aspirin can lower the risk of heart…

Dr. Heart · May 2, 2019 37,836 views

Aspirin's Role in Cardiovascular Risk for Diabetic Patients

Aspirin can lower the risk of serious cardiovascular events in people with diabetes but increases the risk of major bleeding. This podcast discusses the implications of aspirin use in primary prevention, particularly…

Medscape · Mar 27, 2024 8 views

JAZ PAX

@jazpax33 · X

RT @hira__lena: The New England Journal of Medicine'de yayınlanan araştırma, aspirinin daha önce kardiyovasküler bir olay yaşamamış kişile…

Mar 16, 2024 · 1 share · 2,408 followers View post →

Arya Su

@hira__lena · X

The New England Journal of Medicine'de yayınlanan araştırma, aspirinin daha önce kardiyovasküler bir olay yaşamamış kişilerde kardiyovasküler hastalık riskinde anlamlı bir azalma sağlamadığını, ancak büyük kanama riskini önemli ölçüde artırdığını buldu.https://t.co/h5lxCeasWI

Mar 16, 2024 · 2 likes · 1 share · 3,144 followers View post →

Awakened Princess

@GastricpH · X

RT @GenEnergyNotes: https://t.co/bgabVjf4JU https://t.co/anasf4BeCh https://t.co/2pwv9lqaQ3 https://t.co/KUQvfS21iZ https://t.co/zKADHh…

Feb 15, 2024 · 2 shares · 1,008 followers View post →

GE Notes

@GenEnergyNotes · X

https://t.co/bgabVjf4JU https://t.co/anasf4BeCh https://t.co/2pwv9lqaQ3 https://t.co/KUQvfS21iZ https://t.co/zKADHhr9Hb

Feb 14, 2024 · 13 likes · 2 shares · 2,000 followers View post →

Dr Gustavo Leónidas Vera Janavel, MD PhD, MTSAC

@gustavoleonidas · X

RT @EricTopol: The 2nd aspirin trial, in #diabetes, showing the benefit was offset by risk of bleeding @NEJM #ESCCongress https://t.co/RFkU…

Aug 22, 2023 · 67 shares · 1,261 followers View post →

gail simmons

@jurylady5 · X

RT @EricTopol: The 2nd aspirin trial, in #diabetes, showing the benefit was offset by risk of bleeding @NEJM #ESCCongress https://t.co/RFkU…

Jul 29, 2023 · 67 shares · 18,454 followers View post →

BluesDr

@Dr_BluesHeart · X

糖尿病に対する一次予防ではASCEND試験ですねー色々意見があるようですが…

Jul 27, 2023 · 1,583 followers View post →

森川暢 /Toru Morikawa Community Hospitalist @ Nara

@aquariusmed · X

一方でNEJMの論文では糖尿病がある患者のprimary preventionではアスピリンは心血管イベントを減少させましたが、出血を増加させました。 https://t.co/V5tEVRgdrT https://t.co/FfovZyks7Q

Jul 27, 2023 · 2 likes · 4,620 followers View post →

Stef white

@Stefwhite7 · X

RT @EricTopol: The 2nd aspirin trial, in #diabetes, showing the benefit was offset by risk of bleeding @NEJM #ESCCongress https://t.co/RFkU…

Jul 27, 2023 · 67 shares · 97 followers View post →

Jim Paulo Sarsagat

@jimsarsagat · X

RT @EricTopol: The 2nd aspirin trial, in #diabetes, showing the benefit was offset by risk of bleeding @NEJM #ESCCongress https://t.co/RFkU…

Jul 26, 2023 · 67 shares · 1,449 followers View post →

Dr Agibus

@Dr_Agibus · X

@DocRirie @doc_DMP @f_mouquet no no no :D étude ASCEND: https://t.co/bF7aaxRZCp et si on veut suivre les recos francaise qui reposent sur des "avis d'expert":

Mar 14, 2023 · 1 like · 8,939 followers View post →

Vicki Allen Crabb

@crabb_vicki · X

@iambackagain21 @apothecarysees @PierreKory RCTs for unprofitable drugs are impossible? Uh no. He should know this. Do you think he’s intentionally misleading you? https://t.co/ewVOZNEDxD. https://t.co/muhR5AKl28. https://t.co/1BsnVXyINi

Sep 16, 2022 · 5,540 followers View post →

SABOURETCardiologist

@SABOURETCardio · X

@pash22 @AndrewFoy82 @dr_benoy_n_shah @MadalinaGarbi @DavidLBrownMD @djc795 @kaulcsmc @VictorDayan1 @pomyers @Argenscore @ovidiogarciav @dompagano @mmamas1973 @drjohnm One issue is that they prescribed anti platelet in primary prevention based on which large RCT with net clinical benefits? Cf RCT by Armitage et al https://t.co/3t7wAPBQvH

Sep 5, 2022 · 2 likes · 31,093 followers View post →

Alexander Chaitoff

@AlexChaitoff · X

And ASCEND - ASA 100mg vs placebo reduced the risk of major CV events, but increased the risk of bleeding in patients with diabetes. 13/20 https://t.co/mAaW52gMxy https://t.co/Cs5bI4g4ym

Dec 21, 2021 · 4 likes · 1,662 followers View post →

Erik Rafflenbeul

@KardiologieHH · X

RT @cardiomet_CE: 12) The ASCEND trial did in fact show a significant reduction in the primary endpoint with #aspirin vs placebo in #diabet…

Dec 7, 2021 · 2 shares · 8,704 followers View post →

cardio-met

@cardiomet_CE · X

12) The ASCEND trial did in fact show a significant reduction in the primary endpoint with #aspirin vs placebo in #diabetes. See

Dec 7, 2021 · 11 likes · 2 shares · 4,157 followers View post →

Dr. Fusco

@drfusco · X

O uso de aspirina evitou eventos vasculares em pessoas com diabetes e nenhuma doença cardiovascular evidente, mas também causou eventos hemorrágicos importantes. Os benefícios absolutos foram amplamente contrabalançados pelo risco de sangramento. https://t.co/UVBUZHdwM4

Oct 24, 2021 · 313 followers View post →

Miguel Cainzos-Achirica

@miguelcainzos23 · X

@Charles_Kyr @DrMarthaGulati @DBelardoMD @varda88 @purviparwani @MichaelJBlaha Thank you. Actually, ASCEND, led by Oxford investigators, was not negative: HR 0.88. That estimate is quite consistent with the JAMA meta-analysis by Zheng. IMO the key is to avoid patients at increased risk of bleeding https://t.co/PFk4wiihL8

Aug 21, 2021 · 3 likes · 1,383 followers View post →

Therapeutics Initiative

@Drug_Evidence · X

5/7 Ex. 4: What about effect of ASA in pts with #diabetes?

Apr 23, 2021 · 3 likes · 1 share · 7,016 followers View post →

MCS

@MedComServices · X

RT @DrStarWolf: #Doctoctoc #cardiotoctoc On est d’accord que l’aspirine en prév 1aire même chez les diabétiques c’est non ? Mon prat a déc…

Jan 28, 2021 · 1 share · 506 followers View post →

Kabuto

@DrStarWolf · X

#Doctoctoc #cardiotoctoc On est d’accord que l’aspirine en prév 1aire même chez les diabétiques c’est non ? Mon prat a déclenché une réaction allergique en en mettant, je l’arrête et j’essaie de laisser un petit mot https://t.co/ijcCUetgZi https://t.co/X7mtLAGuSH

Jan 28, 2021 · 1 like · 1 share · 8,254 followers View post →

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA · X

@DBelardoMD @RonBlankstein @DrMarthaGulati @mmamas1973 @purviparwani @iamritu @ErinMichos @ajaykirtane @AChoiHeart @bkolskk @rblument1 @cardioPCImom @cardio10s @DrOstfeld @aayshacader @HeartOTXHeartMD @DocSavageTJU @AnastasiaSMihai @GiuseppeGalati_ @drtracykpaul @pnatarajanmd Having said that, our current paradigm for 1°: #ASPREE (https://t.co/vMqWjWVfYx) and other trials and #ASCEND (https://t.co/3yZhYjEiGg) show us even “higher risk” primary care may not benefit from aspirin 3/

Jan 22, 2021 · 9,799 followers View post →

sales_un

@sales_un · X

@ch_tiane @AusAntiLeft @ellymelly The evidence certainly suggests that it works but unless you get a few thousand people in an RCT you just don't know because of possible confounders. We have recommended aspirin in diabetes for years. Embarrassing when the RCT says we weren't quite right https://t.co/vBfqHPoWl3

Oct 7, 2020 · 646 followers View post →

Armando Arriaga

@AlvarezArmandoS · X